RGEN
HealthcareRepligen Corporation · Medical - Instruments & Supplies · $6B
What is Repligen Corporation?
Repligen Corporation is a bioprocessing technology company serving the biological drug manufacturing industry. Its products help life sciences and biopharmaceutical companies purify, filter, and analyze biologics throughout the drug production process.
Repligen makes money by selling specialized equipment, consumables, and systems used in the manufacturing of biological drugs. Its product lines span chromatography, filtration, and process analytics — covering both upstream cell culture and downstream purification steps. Customers include biopharmaceutical companies, life sciences firms, and diagnostics businesses across North America, Europe, and the Asia Pacific region.
Founded in 1986 and headquartered in Waltham, Massachusetts, Repligen has grown into a recognized supplier of bioprocessing tools for global drug manufacturers.
- OPUS pre-packed chromatography columns for biologics purification
- XCell Alternating Tangential Flow filtration systems for upstream processing
- KrosFlo and TangenX tangential flow filtration systems
- SoloVPE and FlowVPE slope spectroscopy process analytics tools
- Protein A ligands and CaptivA chromatography resins
Is RGEN a Good Stock to Buy?
UQS Score rates RGEN as Below Average overall, reflecting meaningful challenges across several key quality dimensions.
The Growth and Risk pillars are the relative bright spots in RGEN's profile. The company operates in a sector with ongoing demand for bioprocessing infrastructure, and its risk profile is assessed as Good — suggesting the balance sheet and operational structure carry manageable near-term exposure.
The Quality and Moat pillars both register as Weak, indicating that returns on capital and competitive durability are areas of concern. The Valuation pillar is rated Elevated, meaning the current price appears to price in a great deal of future optimism.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does RGEN pay dividends?
No — Repligen Corporation does not currently pay a dividend.
Repligen does not currently pay a dividend. As a growth-oriented bioprocessing company, Repligen has historically directed capital back into product development, acquisitions, and expanding its commercial infrastructure rather than returning cash to shareholders through distributions. Income-focused investors should factor this into their assessment.
When does RGEN report earnings?
Repligen reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Repligen's recent results have reflected the broader softness in bioprocessing demand that has affected the sector, as large biopharma customers worked through inventory buildups. The company's growth trajectory remains tied to the recovery pace of the biologics manufacturing market.
For the most recent quarter's results and guidance, visit Repligen's investor relations page directly.
RGEN Price History
-27.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Repligen Corporation?
Based on Repligen Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
RGEN Long-term Outlook
RGEN's Growth pillar is rated Good, suggesting the underlying demand for bioprocessing tools is expected to recover as the biologics industry normalizes. However, the Elevated Valuation pillar indicates that much of this recovery may already be reflected in the share price. The Weak Quality and Moat ratings temper the longer-term outlook, as durable competitive advantages and capital efficiency remain areas to watch.
Growth drivers
- Recovery in biopharma customer spending and inventory normalization
- Expanding biologics pipeline driving demand for purification and filtration tools
- Geographic expansion across Asia Pacific and international markets
Key risks
- Elevated valuation leaves limited margin of safety if growth disappoints
- Weak moat rating suggests pricing power and competitive differentiation may be limited
- Customer concentration among large biopharma companies creates demand volatility
RGEN vs Peers
Repligen operates in a specialized corner of the life sciences tools market, but investors often compare it alongside other healthcare and packaging-adjacent companies.
Bausch + Lomb focuses on eye health products and consumer vision care rather than bioprocessing, representing a different segment of the broader healthcare market.
AptarGroup specializes in drug delivery and dispensing systems, serving pharmaceutical and consumer markets with a more diversified end-market exposure than Repligen.
Frequently Asked Questions
What does Repligen do?
Repligen develops and sells bioprocessing technologies used in the manufacturing of biological drugs. Its products — including chromatography columns, filtration systems, and process analytics tools — help biopharma companies purify and produce biologics more efficiently. The company serves customers across North America, Europe, and the Asia Pacific.
Does RGEN pay dividends?
Repligen does not currently pay a dividend. The company reinvests its capital into product development and business expansion rather than distributing cash to shareholders. Investors seeking income from their healthcare holdings should note this absence.
When does RGEN report earnings?
Repligen reports financial results on a quarterly basis, as is standard for US-listed companies. For the exact timing of upcoming earnings releases, check Repligen's investor relations page or your brokerage's earnings calendar.
Is RGEN a good stock to buy?
UQS Score rates RGEN as Below Average overall. While the Growth and Risk pillars show relative strength, the Quality and Moat pillars are rated Weak, and Valuation is Elevated. This combination suggests investors should weigh recovery potential carefully against current pricing. The full pillar breakdown is available to Pro members.
Is RGEN overvalued?
The UQS Valuation pillar for RGEN is rated Elevated, indicating the stock appears priced above what fundamentals alone might justify. This doesn't mean the stock will decline, but it does suggest limited margin of safety if growth expectations are not met. View the complete valuation analysis with a Pro account.
How does RGEN compare to its competitors?
Repligen occupies a specialized niche in bioprocessing tools, distinct from broader healthcare companies like Bausch + Lomb or drug delivery specialists like AptarGroup. Its competitive positioning depends heavily on relationships with biopharma manufacturers and the depth of its product portfolio across filtration, chromatography, and analytics.
What is RGEN's market cap bracket?
Repligen is classified as a mid-cap stock. This places it in a range that typically offers more growth potential than large-cap peers but with greater volatility than the largest healthcare companies. Mid-cap bioprocessing companies can be sensitive to shifts in biopharma spending cycles.
Who founded Repligen?
Repligen was founded in 1986. Details on the founding team are widely available through public sources, including the company's own history page and financial filings. The company has evolved significantly since its founding, shifting focus toward bioprocessing tools over time.
Is RGEN a long-term quality indicator?
From a long-term quality perspective, RGEN's profile presents a mixed picture. The Weak ratings on Quality and Moat pillars suggest that durable competitive advantages and capital efficiency need improvement for the company to rank among the highest-quality names in the sector. The Growth pillar offers some longer-term optimism tied to biologics demand.
What is the main competitive advantage of Repligen?
Repligen's positioning comes from its broad portfolio of specialized bioprocessing consumables and systems that are embedded in customers' manufacturing workflows. Switching costs can be meaningful once a product is validated in a regulated drug manufacturing process, though the UQS Moat pillar rates this advantage as Weak relative to sector peers.
What sector does RGEN belong to?
Repligen operates in the Healthcare sector, specifically within the life sciences tools and services segment. It serves biopharmaceutical and diagnostics companies rather than developing drugs itself, making it a pick-and-shovel play on the broader biologics manufacturing industry.
Is RGEN a growth stock or value stock?
Based on UQS pillar ratings, RGEN leans toward the growth category — the Growth pillar is rated Good, reflecting expectations tied to bioprocessing market recovery. However, the Elevated Valuation pillar means it does not screen as a value opportunity at current levels. It sits in a higher-expectation, higher-risk zone of the growth spectrum.
Unlock Full RGEN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact scores across all five UQS pillars
- ✓Access complete financial metrics and trend data
- ✓Compare RGEN against sector peers side by side
- ✓See the full Quality and Moat deep-dive breakdown
- ✓Get valuation context relative to bioprocessing peers
- ✓Track RGEN alongside your full watchlist in Pro
Pro Analysis
RGEN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 43.9 | 22.3 | 33.0 | 73.2 | 70.1 | 32.5 | +4.3 |
| May 10, 2026 | 39.6 | 9.0 | 33.0 | 73.3 | 39.5 | 56.9 | 0.0 |
| May 8, 2026 | 39.6 | 9.0 | 33.0 | 73.3 | 39.5 | 56.6 | -3.3 |
| May 7, 2026 | 42.9 | 20.2 | 33.0 | 73.3 | 68.6 | 31.2 | -0.2 |
| Apr 26, 2026 | 43.1 | 20.2 | 33.0 | 73.9 | 68.6 | 31.5 | +0.1 |
| Apr 21, 2026 | 43.0 | 20.2 | 33.0 | 73.9 | 68.6 | 30.8 | 0.0 |
| Apr 19, 2026 | 43.0 | 20.2 | 33.0 | 73.8 | 68.6 | 30.8 | 0.0 |
| Apr 18, 2026 | 43.0 | 20.2 | 33.0 | 73.8 | 68.6 | 31.3 | -1.2 |
| Apr 15, 2026 | 44.2 | 20.2 | 33.0 | 73.8 | 68.6 | 39.1 | 0.0 |
| Apr 14, 2026 | 44.2 | 20.2 | 33.0 | 73.8 | 68.6 | 39.0 | 0.0 |
RGEN — Pillar Breakdown
Quality
— 21.9/100 (25%)Repligen Corporation currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 73.5/100 (20%)Repligen Corporation demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 70.1/100 (15%)Repligen Corporation maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 31.7/100 (15%)Repligen Corporation appears expensively valued relative to its fundamentals and growth prospects.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 33/100 (25%)Repligen Corporation operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for RGEN.
Score Composition
Financial Data
More Stock Analysis
How is the RGEN UQS Score Calculated?
The UQS (Unified Quality Score) for Repligen Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Repligen Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Repligen Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.